Literature DB >> 22261236

Retention of clinical trial participants in a study of nongonococcal urethritis (NGU), a sexually transmitted infection in men.

Jeannette Y Lee1, Shelly Y Lensing, Jane R Schwebke.   

Abstract

Nongonococcal urethritis (NGU), an inflammation of the urethra not caused by gonorrhea, is the most common urethritis syndrome seen in men in the United States. It is a sexually transmitted infection commonly caused by Chlamydia trachomatis, a pathogen which occurs more frequently in African-American men compared to white men. The purpose of this study was to investigate factors related to retention of study participants in a randomized, double-blinded clinical trial that evaluated four treatment regimens for the treatment of NGU. After the one-week treatment period, follow-up visits were scheduled during days 15-19 and days 35-45. Participants were phoned prior to scheduled appointments to encourage attendance, and contacted after missed appointments to reschedule their clinic visits. Of the 305 male study participants, 298 (98%) were African-American, 164 (54%) were 25 years of age or younger, and 80 (31%) had a post-secondary school education. The overall retention rate was 75%. Factors associated with study completion were educational level attained and clinical center. Participants with higher levels of education were more likely to complete the study. Clinical centers with the highest retention rates also provided the highest monetary incentives for participation. The retention rate for this study suggests that strategies are needed for improving the proportion of study participants that complete a clinical trial among young men with a sexually transmitted disease. These strategies may include increasing contacts with study participants to remind them of scheduled study visits using text messaging or social media and the use of financial incentives.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22261236      PMCID: PMC3346855          DOI: 10.1016/j.cct.2011.12.004

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  39 in total

Review 1.  Clinical practice. Genital chlamydial infections.

Authors:  Jeffrey F Peipert
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

2.  HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment.

Authors:  Peter A Newman; Naihua Duan; Kathleen J Roberts; Danielle Seiden; Ellen T Rudy; Dallas Swendeman; Svetlana Popova
Journal:  J Acquir Immune Defic Syndr       Date:  2006-02-01       Impact factor: 3.731

3.  Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection.

Authors:  Matthew R Golden; William L H Whittington; H Hunter Handsfield; James P Hughes; Walter E Stamm; Matthew Hogben; Agnes Clark; Cheryl Malinski; Jennifer R L Helmers; Katherine K Thomas; King K Holmes
Journal:  N Engl J Med       Date:  2005-02-17       Impact factor: 91.245

4.  Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials.

Authors:  Primo N Lara; Debora A Paterniti; Christine Chiechi; Corinne Turrell; Claudia Morain; Nora Horan; Lisa Montell; Jose Gonzalez; Sharon Davis; Ari Umutyan; Cynthia L Martel; David R Gandara; Ted Wun; Laurel A Beckett; Moon S Chen
Journal:  J Clin Oncol       Date:  2005-12-20       Impact factor: 44.544

5.  Participant retention in clinical trials of candidate HIV vaccines.

Authors:  Guy de Bruyn; Michael G Hudgens; Patrick S Sullivan; Ann C Duerr
Journal:  J Acquir Immune Defic Syndr       Date:  2005-08-01       Impact factor: 3.731

6.  Participation in research and access to experimental treatments by HIV-infected patients.

Authors:  Allen L Gifford; William E Cunningham; Kevin C Heslin; Ron M Andersen; Terry Nakazono; Dale K Lieu; Martin F Shapiro; Samuel A Bozzette
Journal:  N Engl J Med       Date:  2002-05-02       Impact factor: 91.245

7.  Motivations for participating in an HIV vaccine efficacy trial.

Authors:  Grant Colfax; Susan Buchbinder; Goli Vamshidar; Connie Celum; David McKirnan; Judith Neidig; Beryl Koblin; Marc Gurwith; Brad Bartholow
Journal:  J Acquir Immune Defic Syndr       Date:  2005-07-01       Impact factor: 3.731

8.  Do STD clinic patients who consent to sexual health research differ from those who decline? Findings from a randomized controlled trial with implications for the generalization of research results.

Authors:  Michael P Carey; Theresa E Senn; Peter A Vanable; Patricia Coury-Doniger; Marguerite A Urban
Journal:  Sex Transm Dis       Date:  2008-01       Impact factor: 2.830

9.  Participation in cancer clinical trials: race-, sex-, and age-based disparities.

Authors:  Vivek H Murthy; Harlan M Krumholz; Cary P Gross
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

10.  What about money? Effect of small monetary incentives on enrollment, retention, and motivation to change behaviour in an HIV/STD prevention counselling intervention. The Project RESPECT Study Group.

Authors:  M L Kamb; F Rhodes; T Hoxworth; J Rogers; A Lentz; C Kent; R MacGowen; T A Peterman
Journal:  Sex Transm Infect       Date:  1998-08       Impact factor: 3.519

View more
  2 in total

1.  Predictors of participant retention in infertility treatment trials.

Authors:  Hongying Kuang; Susan Jin; Tracey Thomas; Lawrence Engmann; Karl R Hansen; Christos Coutifaris; Peter Casson; Gregory Christman; Ruben Alvero; Nanette Santoro; Esther Eisenberg; Michael P Diamond; Richard S Legro; Heping Zhang
Journal:  Fertil Steril       Date:  2015-09-03       Impact factor: 7.329

2.  The Use of Technology in Participant Tracking and Study Retention: Lessons Learned From a Clinical Trials Network Study.

Authors:  Shannon Gwin Mitchell; Robert P Schwartz; Anika A H Alvanzo; Monique S Weisman; Tiffany L Kyle; Eva M Turrigiano; Martha L Gibson; Livangelie Perez; Erin A McClure; Sara Clingerman; Autumn Froias; Danielle R Shandera; Robrina Walker; Dean L Babcock; Genie L Bailey; Gloria M Miele; Lynn E Kunkel; Michael Norton; Maxine L Stitzer
Journal:  Subst Abus       Date:  2015-02-11       Impact factor: 3.716

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.